Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Ahmet Demirkazik"'
Autor:
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Zehra Sucuoglu Isleyen, Jamshid Hamdard, Sedat Yildirim, Tolga Dogan, Selver Isik, Abdussamet Celebi, Burcu Belen Gulbagci, Nail Paksoy, Mutlu Dogan, Haci Mehmet Turk, Ahmet Bilici, Ali Murat Tatli, Sinem Akbas, Nedim Turan, Ilhan Hacibekiroglu, Gamze Gokoz Dogu, Adnan Aydiner, Ahmet Taner Sumbul, Serap Akyurek, Merih Yalciner, Ahmet Demirkazik, Pinar Gursoy, Musa Baris Aykan, Elif Sahin, İbrahim Karadag, Osman Kostek, Muhammed Muhiddin Er, Mehmet Artaç, Yakup Duzkopru, Dincer Aydin, Deniz Isik, Yusuf Karakas, Saadettin Kilickap, Cihan Erol, Bilgin Demir, Burak Civelek, Yakup Ergun, Muhammed Bulent Akinci, Izzet Dogan, Nuri Karadurmus, Perran Fulden Yumuk, Mehmet Ali Nahit Sendur
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brai
Externí odkaz:
https://doaj.org/article/dfd4fc84465f4b4985707fa241e217b7
Autor:
Mustafa Karaagac, Mehmet Artac, Caglayan Geredeli, Melek Karakurt Eryilmaz, Mahmut Selman Yildirim, Tuba Akkuloglu, Ali Inal, Abdurrahman Isikdogan, Hakan Bozcuk, Ahmet Demirkazik
Publikováno v:
Medicine Science, Vol 9, Iss 1, Pp 255-60 (2020)
Results from studies in several cancers on single nucleotide polymorphisms (SNPs) suggest that DNA repair capacity may have prognostic implication for disease recurrence, survival, and responses to treatment. This study aimed to evaluate the potentia
Externí odkaz:
https://doaj.org/article/4f9cba6494ec43678eddb650bbf753de
Autor:
Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba, Gabriella Gálffy, Ülkü Yilmaz Turay, Ahmet Demirkazik, Gunta Purkalne, Attila Somfay, Zsolt Pápai-Székely, Erzsébet Rásó, Gyula Ostoros
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical
Externí odkaz:
https://doaj.org/article/d7176d935e0a4a359302b37df3fb11e5
Autor:
Huseyin Abali, Ahmet Demirkazik
Publikováno v:
Journal of Oncological Sciences, Vol 3, Iss 1, Pp 1-2 (2017)
Externí odkaz:
https://doaj.org/article/84a89af61b5448ba9ea85ff14b2c5926
Autor:
Dilsa Mizrak, Emra Asfuroglu Kalkan, Ali Alkan, Halis Yerlikaya, Elif Berna Koksoy, Ebru Karci, Gungor Utkan, Ahmet Demirkazik
Publikováno v:
Journal of Oncological Sciences, Vol 2, Iss 1, Pp 27-28 (2016)
Background: Hyponatremia is one of the most common electrolyte abnormalities seen in hospitalized patients. In cancer patients, it's generally related to syndrome of inappropriate ADH secretion (SIADH). Case Report: Here, we report a breast cancer pa
Externí odkaz:
https://doaj.org/article/f75bd9443ff947aa8c176667fe6b3cad
Autor:
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukbiricik, Serkan Menekse, Eyyüp Cavdar, Akın Ozturk, Esma Türkmen Bekmez, Serdal Turhal, Sadettin Kilickap, Hasan Çağrı Yildirim, Başak Oyan, Asude Aksoy, Fatma Paksoy Turkoz, Engin Kut, Nuran Katgi, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilanci, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:865-875
Objectives: To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods: We retrospectively evalu
Autor:
Mustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, Nuri Karadurmuş, Ahmet Sezer, Mehmet Ali Nahit Şendur, Semra Paydaş, Mehmet Artaç, Perran Fulden Yumuk, Pinar Gürsoy, Mükremin Uysal, Hasan Şenol Coşkun, Ali Murat Tatli, Fatih Selçukbiricik, Umut Dişel, Elif Berna Köksoy, Deniz Can Güven, Muzaffer Uğrakli, Erman Akkuş, Şebnem Yücel, Cihan Erol, Serdar Karakaya, Teoman Şakalar, Nijat Khanmammadov, Nail Paksoy, Ahmet Demirkazik
Publikováno v:
Medicine. 101(50)
Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterat
Autor:
Emre Yekedüz, Elif Berna Köksoy, Sati Coşkun Yazgan, Göktürk Karataş, Filiz Çay Şenler, Güngör Utkan, Hakan Akbulut, Ahmet Demirkazik, Yüksel Ürün
Publikováno v:
Anti-cancer drugs. 33(10)
Immune checkpoint inhibitors (ICIs) have started a new era in treating patients with cancer. The effect of comorbidities and concomitant drug use on ICIs have become of interest in those patients. Data about the impact of hyperglycemia on response to
Autor:
Sadettin Kilickap, Mutlu Hizal, Ahmet Gulmez, Okan Avci, Burak Yasin Aktas, Havva Yesil Cinkir, Emir Celik, Mustafa Gürbüz, Berna Oksuzoglu, Ali Murat Tatli, Gulhan Ipek Deniz, Cihan Erol, Erdem Sen, Fulden Yumuk, A İlhan, Şebnem Yücel, Semra Paydas, Ozkan Alan, Engin Kut, Fatih Karatas, Atakan Demir, Murat Ayhan, Bulent Yalcin, Halil Taskaynatan, Tugba Basoglu, Serkan Menevse, Deniz Tataroğlu Özyükseler, Nadiye Akdeniz, Sinan Koca, Mustafa Karaagac, Burak Bilgin, Didem Sener Dede, Mehmet Ali Nahit Sendur, Muhammed Bulent Akinci, Izzet Dogan, Ahmet Demirkazik, Teoman Sakalar
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2145-2152
The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that invest
Autor:
Serhat Hayme, Mustafa Gürbüz, Bilgin Karaalioğlu, Yuksel Urun, Elif Gizem Aktaş, Serpil Dizbay Sak, Ahmet Demirkazik, Erman Akkus, Hilal Özakıncı, Güngör Utkan, Elif Berna Köksoy
Publikováno v:
Journal of Oncological Sciences. 7:20-24